1KPA.F PROTARA THERAPEUT.DL-001
- Market cap
- EUR 145M
- P/E
- -
- P/B
- 1.02x
- ROE
- -57.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1KPA.F undervalued?
Graham numberThe Graham number of PROTARA THERAPEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PROTARA THERAPEUT.DL-001 fundamental analysis
No fundamental analysis for PROTARA THERAPEUT.DL-001 yet.
PROTARA THERAPEUT.DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PROTARA THERAPEUT.DL-001
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for pa…
Full company profilePROTARA THERAPEUT.DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PROTARA THERAPEUT.DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -47.5M | -37.5M | -43.6M | -49.2M | -64.5M | -88.1M |
| EBITDA | - | -64.6M | -43.3M | -48.8M | -64.2M | -87.8M |
| Net Income | -47.3M | -66.0M | -40.4M | -44.6M | -57.4M | -81.5M |
| EPS | -4.21 | -5.85 | -3.56 | -1.27 | -1.07 | -1.36 |
| Balance Sheet | ||||||
| Total Assets | 173M | 113M | 79.0M | 181M | 209M | 157M |
| Total Liabilities | 10.7M | 11.2M | 10.6M | 14.3M | 13.1M | 15.5M |
| Shareholders' Equity | 162M | 102M | 68.3M | 167M | 196M | 141M |
| Cash & Short-term Investments | 35.7M | 24.1M | 39.6M | 163M | 49.7M | 25.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -34.5M | -26.5M | -37.6M | -35.8M | -56.4M | -73.6M |
| Capital Expenditure | 596K | 120K | 45.0K | 63.0K | 94.0K | 964K |
| Free Cash Flow | -35.1M | -26.6M | -37.6M | -35.9M | -56.5M | -75.0M |
| Ratios | ||||||
| ROE | -29.2% | -64.6% | -59.2% | -26.7% | -29.2% | -57.8% |
| ROA | -27.4% | -58.2% | -51.2% | -24.6% | -27.4% | -52.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
PROTARA THERAPEUT.DL-001 dividends
PROTARA THERAPEUT.DL-001 has not paid dividends in the last 5 fiscal years.
Who owns PROTARA THERAPEUT.DL-001
- Insiders 2.21%
- Institutions 75.44%
- Public & others 22.36%
- Shares outstanding 61.6M
- Free float 57.4M
PROTARA THERAPEUT.DL-001 company profile
- Company name
- PROTARA THERAPEUT.DL-001
- Ticker
- 1KPA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- 345 Park Avenue South, New York, NY, United States, 10010
- Phone
- 646 844 0337
- Website
- protaratx.com
About PROTARA THERAPEUT.DL-001
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
PROTARA THERAPEUT.DL-001 management
10- Mr. Jesse SheffermanCo-founder, CEO, President & Director · born 1972
- Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.Co-Founder, Chief R&D Officer · born 1981
- Mr. Patrick Fabbio M.B.A.Chief Financial Officer · born 1968
- Ms. Hannah FryVP, Principal Accounting Officer & Controller · born 1991
- Ms. Justine O'MalleySenior Vice President of Investor Relations & Corporate Affairs
- Ms. Mary J. Grendell J.D.General Counsel & Corporate Secretary
- Dr. Shane Williams Ph.D.Chief People Officer
- Mr. William ConklingChief Commercial Officer · born 1971
- Carla Beckham M.D., Ph.D.Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist
- Dr. Neal D. Shore F.A.C.S., M.D.Medical Director of START Carolinas/ Carolina Urologic Research Center